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Objective: Cell-based gene therapy can enhance the effects of cell transplantation by temporally and spatially
regulating the release of the gene product. The purpose of this study was to evaluate transient matrix metallopro-
teinase inhibition by implanting cells genetically modified to overexpress a natural tissue inhibitor of matrix met-
alloproteinases (tissue inhibitor of matrix metalloproteinase-3) into the hearts of mutant (tissue inhibitor of matrix
metalloproteinase-3–deficient) mice that exhibit an exaggerated response to myocardial infarction. Following
a myocardial infarction, tissue inhibitor of matrix metalloproteinase-3–deficient mice undergo accelerated cardiac
dilatation and matrix disruption due to uninhibited matrix metalloproteinase activity. This preliminary proof of
concept study assessed the potential for cell-based gene therapy to reduce matrix remodeling in the remote myo-
cardium and facilitate functional recovery.
Methods: Anesthetized tissue inhibitor of matrix metalloproteinase-3–deficient mice were subjected to coronary
ligation followed by intramyocardial injection of vector-transfected bone marrow stromal cells, bone marrow
stromal cells overexpressing tissue inhibitor of matrix metalloproteinase-3, or medium. Functional, morphologic,
histologic, and biochemical studies were performed 0, 3, 7, and 28 days later.
Results:Bone marrow stromal cells and bone marrow stromal cells overexpressing tissue inhibitor of matrix met-
alloproteinase-3 significantly decreased scar expansion and ventricular dilatation 28 days after coronary ligation
and increased regional capillary density to day 7. Only bone marrow stromal cells overexpressing tissue inhibitor
of matrix metalloproteinase-3 reduced early matrix metalloproteinase activities and tumor necrosis factor a levels
relative to medium injection. Bone marrow stromal cells overexpressing tissue inhibitor of matrix metalloprotei-
nase-3 were also more effective than bone marrow stromal cells in preventing progressive cardiac dysfunction,
preserving remote myocardial collagen content and structure, and reducing border zone apoptosis for at least
28 days after implantation.
Conclusions: Tissue inhibitor of matrix metalloproteinase-3 overexpression enhanced the effects of bone marrow
stromal cells transplanted early after a myocardial infarction in tissue inhibitor of matrix metalloproteinase-3–
deficient mice by contributing regulated matrix metalloproteinase inhibition to preserve matrix collagen and
improve functional recovery.Supplemental material is available online.
We recently demonstrated that the paracrine benefits of cell
transplantation1 canbeenhancedby transfecting the implanted
cells with genes to increase their cytokine production2-4; these
‘‘cell-based gene therapies’’ permit the temporally and spa-
tially regulated release of the gene product. This study
assessed the potential for this technique to reduce post–
myocardial infarction (MI) matrix remodeling in the remote
myocardium and facilitate functional recovery. Cell-based
gene therapy could represent a clinically relevant method to
prevent congestive heart failure.
After an MI, diminished elasticity and increased wall
stress cause the infarcted region to thin and expand while
the remote myocardium undergoes extensive remodeling.
An increase in the activity of matrix metalloproteinases
(MMPs) relative to that of their natural tissue inhibitors
(TIMPs) contributes to ventricular dilatation and dysfunc-
tion5 through remodeling of the extracellular matrix
(ECM), a dynamic structure that provides a scaffold for car-
diomyocytes, facilitates contraction, and supports homeo-
stasis.6 Although the importance of modifying post-MI
matrix remodeling using MMP inhibitors has been estab-
lished,7 clinically relevant strategies have been difficult to
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ADAM ¼ a disintegrin and a metalloproteinase
domain
ANOVA ¼ analysis of variance
BMSC ¼ bone marrow stromal cell
ECM ¼ extracellular matrix
ELISA ¼ enzyme-linked immunosorbent assay
FAC ¼ fractional area change
LV ¼ left ventricular
MI ¼ myocardial infarction
MMP ¼ matrix metalloproteinase
TIMP ¼ tissue inhibitor of matrix
metalloproteinase
timp3/ ¼ TIMP-3-deficient mice
TNF-a ¼ tumor necrosis factor a
TUNEL ¼ terminal deoxynucleotidyl
transferase–mediated dUTP nick
end labeling
VEGF ¼ vascular endothelial growth factor
implement8: Chronic administration of MMP inhibitors9,10
and the initial clinical trials11 were not beneficial, and gene
therapies12 are nonspecific.10 Implanting cells genetically
modified to overexpress TIMP-3 into the heart after an MI
may regulate MMP inhibition in the infarcted and remote re-
gions,10 establishing the proof of concept for cell-based gene
therapy as an effective, clinically relevant approach to ma-
trix modulation.
We evaluated cell-based gene therapy in TIMP-3 deficient
(timp-3/) mice, a model in which we previously reported
spontaneous heart failure after age 12 months due to unop-
posed ECM degradation13,14 and premature heart failure in
response to coronary ligation.15
MATERIALS AND METHODS
Animals
All experimental procedures performed on animals were approved by the
Animal Care Committee of the University Health Network, according to the
‘‘Guide for the Care and Use of Laboratory Animals’’ (National Academy
Press, 1996). Eight- to 10-week-old C57BL/6 mice were obtained from
Jackson Laboratories (Bar Harbor, Maine). Timp-3/C57BL/6 mice were
generated as previously described.13
In Vitro Studies
Bone marrow stromal cells: Isolation, transfection, and
characterization. Procedures to generate the bone marrow stromal
cells (BMSCs) employed in these studies are described in detail in Appendix
E1 (supplementary methods). Briefly, adherent cells harvested from
C57BL/6 mice were transfected by liposomal lipofectamine 2000 (Invitro-
gen) with a purified plasmid consisting of cDNA for murine TIMP-3 cloned
into pcDNA3.1þ (Invitrogen), as previously described.16 Cellular TIMP-3
mRNA levels were assessed by semiquantitative reverse-transcriptase poly-
merase chain reaction, using specific primers, as previously described.17
Protein levels of synthesized (BMSC lysate) and secreted (supernatant)
TIMP-3 were evaluated with an immunoblotting procedure. MMP-2 protein
levels in the cultured cells and culture medium were quantified by Western
blot. MMP-2 activities were evaluated using gelatin zymography, as previ-
ously described.14
In Vivo Studies
Surgical procedure. In the timp-3/mouse model, the left coronary
artery was permanently ligated proximally under the left atrial appendage
through a thoracotomy. Ischemia was confirmed by the appearance of hypo-
kinesis and pallor distal to the occlusion, and by ST elevation (electrocardio-
graphic monitoring). The animals were randomly separated into 3 groups.
At 5 minutes after ligation, BMSCs transfected 3 days earlier with TIMP-
3 plasmid (BMSC-T3 group) or vector (BMSC group) were delivered by
3 direct, intramyocardial injections (13 105 cells in 5 mL of Iscove’s mod-
ified Dulbecco’s medium per injection) into 3 separate points within the in-
farcted area (identified visually as a dark brown area). Control animals
(medium control group) received 3 injections of culture medium (5 mL
per injection). Early mortality for the surgical procedure was 26%. Assess-
ments were performed before coronary ligation and cell or medium implan-
tation (0 days), early after coronary ligation and implantation (3 and 7 days),
and late after ligation/implantation (28 days). Measurements were taken in
a blinded fashion so that operators performing echocardiographic, histo-
logic, and biochemical analyses were not aware of the groups to which
the animals were randomized.
Functional assessment. Left ventricular (LV) dilatation and systolic
functionwere evaluated by echocardiography (SequoiaC256System, Siemens
Medical, Malvern, Penn.); 15-MHz linear array transducer) prior to and 3, 7,
and 28 days after MI and cell or medium implantation (n ¼ 6 per group).
Detailed procedures are described in Appendix E1 (supplementary methods).
Fractional area change (FAC) was calculated from 2-dimensional images.
Morphometric assessment. At 28 days after implantation (n ¼ 6
each for medium, BMSC, BMSC-T3 groups; n ¼ 3 for normal myocar-
dium), hearts were fixed and sliced transversely (1-mm-thick slices), then
photographed for the measurement of infarct area (as a percentage of LV
area) and body weight–indexed LV chamber volume. Detailed procedures
are described in Appendix E1 (supplementary methods).
Remote myocardial collagen content and structure.
Twenty-eight days after implantation, LV slices from the perfusion-fixed
hearts (n¼ 6 each for medium, BMSC, BMSC-T3 groups; n¼ 4 for normal
myocardium) were paraffin embedded, cut into 15-mm-thick sections, and
stained with 0.1% picrosirius red as previously described.18 Sections
were imaged using a laser scanning confocal microscope (MRC 1024,
Bio-Rad, Hercules, Calif). Five fields (n ¼ 5 per heart) were randomly se-
lected from the remote myocardium (viable tissue located in the lateral
wall of the LV), as previously described.6 For each image, total collagen
content (% pixel2) and average perimysial collagen fibril length and diam-
eter (in micrometers after image scaling) were measured.
Apoptosis. Frozen sections from hearts harvested on days 3, 7, and 28
following implantation (n ¼ 5 per group per time point) were subjected to
terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling
(TUNEL) staining (in situ cell death detection kit AP, Roche, Basel, Swit-
zerland), as previously described.19 For each sample, apoptotic nuclei
counts from 5 random microscope fields from the infarct border zone (iden-
tified using hematoxylin and eosin staining for basic histologic structures on
the preceding serial section) were averaged, and apoptosis was expressed as
the mean percentage of apoptotic nuclei/total nuclei per field.
Capillary density. Frozen sections from hearts harvested on days 3
and 7 following implantation (n ¼ 5 per group per time point) were immu-
nohistochemically stained with immunoglobulin G rat-anti-mouse CD31
antibody. For each sample, capillary density per millimeter squared was cal-
culated from the mean number of capillaries (large, CD31þ structures)
counted in 5 random, high-powered microscope fields (0.05 mm2) from
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PFIGURE 1. In vitro analysis of tissue inhibitor of matrix metalloproteinase-3 (TIMP-3) andmatrix metalloproteinase-2 (MMP-2).A, Transfection efficiency.
b-Galactosidase control vector expression (in blue) 3 days after transfection into bone marrow stromal cells (BMSCs;3400). B, C, Semiquantitative reverse-
transcriptase polymerase chain reaction (B) and densitometry (TIMP-3 mRNA levels normalized relative to glyceraldehyde-3-phosphate dehydrogenase
[GAPDH] expression: TIMP-3/GAPDH). (C), Analyses showing TIMP-3 mRNA levels and GAPDH expression at days (D) 1, 2, 3, and 6 after cultured
BMSCs were transfected with timp-3 (BMSC-T3) or vector (BMSC). Bsl, baseline; C1, control sample without reverse transcription; T3, TIMP-3 plasmid;
C2, solution control; n ¼ 5 gels in (C). *P< .05 compared with Bsl. D, E, Time course analysis of TIMP-3 protein levels by immunoblot in cell lysis and
supernatant at Bsl and days (D) 3, 6, and 10 after timp-3 transfection. Bsl, Nontransfected cells (cell lysis) or culture medium (supernatant); MW, molecular
weight; n ¼ 6 gels in E. **P<.01 compared with Bsl; #P<.001 compared with Bsl. F–H, Gelatin zymography (F) with immunoblot (G) and densitometry
analysis (H), showing a significant reduction (30%; P<.01) in MMP-2 activity in the supernatant, with no difference in MMP-2 expression in the cell lysis
or supernatant or in internal standard GAPDH expression, 3 days after transfection in the BMSC-T3 group relative to the BMSC group. PC, Positive control;
n ¼ 6 samples per group in H, equal amounts of protein loaded. Data are mean  standard error of the mean.the infarct border zone (identified using hematoxylin and eosin staining on
the preceding serial section).
Myocardial MMP expression and activity. Myocardial sam-
ples from animals sacrificed on days 3, 7, and 28 after implantation (n ¼ 6
mice per group per time point) were snap-frozen. Half of each heart homog-
enate was treated at 4C for 1 hour with an extraction buffer for determina-
tion of MMP-2 and -9 activities. The other half was treated at 4C for 1 hour
with an extraction buffer containing 0.15 NaCl, 5 mmol/L ethylenediamine-
tetraacetic acid, 1% Triton X-100, 10 mmol/L Tris-Cl, and small amounts
of proteinase inhibitor cocktail for measurement of MMP-2 and -9 protein
levels. Protein levels and activities were evaluated as described in Appendix
E1 (supplementary methods), with integrated density values of active
MMP-9 and -2 used as markers of MMP-9 and -2 activation.
Myocardial tumor necrosis factor a levels. Mice were sacri-
ficed on days 3 and 7 after implantation (n¼ 6 per group). Hearts from nor-
mal mice (n ¼ 4) were collected as normal controls. The myocardial tissue
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a (TNF-a) levels were quantified using enzyme-linked immunosorbent as-
say (ELISA) with commercial Murine TNF-a ELISA Kit (Endogen, Rock-
ford, Ill.) as per manufacturer’s instructions. Each sample at each time point
was performed in triplicate, then averaged.
Statistical Analyses
Results are expressed as mean  standard error of the mean unless other-
wise specified. Data recorded at several time points were analyzed using
2-way, repeated measures analysis of variance (ANOVA; to detect time and
group effects) followed (when significant) by Bonferoni’s post hoc multiple
comparison test, or using1-wayANOVAfollowedbyTukeymultiple compar-
ison test. Unless otherwise specified, data recorded at a single time point were
analyzedusing1-wayANOVAfollowedbyNewman–Keulsmultiple compar-
ison test. Differences were considered statistically significant at P< .05.
RESULTS
In Vitro Studies
Appendix E1 (supplementary results) describes the phe-
notype of cultured BMSCs at passage 20 that were employed
for the in vivo studies. The efficiency of gene transfection
was 15%  2%. As shown in Figure 1, TIMP-3 protein
levels in the BMSC lysate (synthesized TIMP-3) and super-
natant (secreted TIMP-3) were elevated for at least 6 days af-
ter timp-3 transfection (P< .01), and MMP-2 activity was
decreased in medium cultured with BMSC-T3 (P< .05 vs
BMSC), confirming that the TIMP-3 expressed by the
BMSC-T3 cells was functional (Figure 1).
In Vivo Studies
TIMP-3 overexpression reduced myocardial MMP
activity. After MI, cardiac MMP-9 and MMP-2 activities
increased. Gelatin zymography provided an estimate of
protease activity (after removal of any inhibition by natural
TIMPs). By this measure, BMSC-T3 implantation signifi-
cantly reduced the activities of both MMP-9 (P< .01 vs
BMSC, P < .05 vs medium) and MMP-2 (P < .01 vs
BMSC and medium) at 3 days after cell transplantation (Fig-
ure 2, A and B), despite the fact that neither MMP-9 nor -2
protein levels (assessed by immunoblotting, relative to inter-
nal standard glyceraldehyde-3-phosphate dehydrogenase
levels) differed significantly among groups at this time point
(data not shown). No significant differences in MMP-9
and -2 expressions or activities were observed among groups
beyond 3 days after transplantation. Implantation of vector-transfected BMSCs did not significantly change MMP activ-
ities compared to medium implantation at any time point.
TIMP-3 overexpression reduced myocardial TNF-a
levels. MI significantly increased myocardial TNF-a levels
(from 0.21  0.01 pg/mg of TNF-a in the normal myocar-
dium), producing a spike during the acute phase (1.67 
0.2 pg/mg), followed by a reduction on day 7 (to 1.22 
0.04 pg/mg) in the medium recipients. BMSC-T3 implanta-
tion decreased TNF-a levels during the acute phase (to 1.01
 0.06 pg/mg; P< .05 vs BMSC and medium), but BMSC
implantation alone did not (1.49  0.2 pg/mg). The decrease
in TNF-a levels persisted at day 7 in the BMSC-T3 group,
at which time levels were statistically similar among the
groups.
TIMP-3 overexpression enhanced the early reduction of
border zone apoptosis by BMSCs. Three days after im-
plantation, TUNEL staining revealed a significant reduction
in apoptosis in the border zone of BMSC-implanted hearts
relative to medium controls (P < .05). Implantation of
BMSC-T3 cells significantly enhanced the early antiapop-
totic effect of BMSC implantation (P< .05 vs BMSC),
which persisted in the BMSC-T3 group at day 7 (P< .05
vs medium, Figure 2, C to G). No significant differences
were observed among groups at day 28.
TIMP-3 overexpression enhanced the preservation of
remote myocardial collagen by BMSCs. MI resulted in
significant fragmentation and thinning of the matrix fibrils
(Figure 3, A to D). Compared with medium injection,
BMSC and BMSC-T3 transplantation significantly reduced
collagen degradation in the remote myocardium at day 28
after cell implantation (P< .05 for all groups; Figure 3E).
Compared with the medium control group, both length and
diameter of the collagen fibrils were preserved by BMSC im-
plantation (P< .05 for both measures). These effects were
significantly enhanced with BMSC-T3 implantation (P<
.05 for both measures vs BMSC and medium control group;
Figure 3, F and G).
TIMP-3 overexpression delayed early blood vessel
formation in the border zone. Following MI, medium-in-
jected hearts exhibited low capillary densities in the borderFIGURE 2. In vivo analysis of matrix metalloproteinase (MMP) activity and apoptosis. A, B, Densitometry analyses estimatingMMP activity in myocardial
extracts at days 3, 7, and 28 after implantation of culture medium, bone marrow stromal cells (BMSCs), or timp-3-transfected BMSCs (BMSC-T3). The pooled
results demonstrate that MMP-9 (A) and MMP-2 (B) gelatinolytic activities were reduced at day 3 after implantation of BMSC-T3 (n¼ 6 per group per time
point). Gelatin zymography does not measure what activity is inactivated by natural inhibitors in vivo. C–F, Representative light micrographs (3400) illus-
trating terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling staining of apoptotic cells (arrows) in the border zone of mouse hearts 3 days
after implantation of medium (C), BMSCs (D), or BMSC-T3 (E). Normal myocardium (No MI, F) is presented as a positive control. Scale bar¼ 50 mm in (C–
F). G, Apoptotic nuclei (expressed as a% of total cells per field on days [D] 3, 7, and 28 after implantation; n¼ 5 per group per time point) were significantly
reduced at D3 with BMSC implantation, and further reduced with BMSC-T3 implantation. The depression in apoptotic cell numbers persisted at D7 in the
BMSC-T3 compared with the medium group. No significant differences were observed between groups at D28. Data are mean standard error of the mean.
*P< .05 versus medium, **P< .01 versus medium; #P< .05 versus BMSCs; zP< .01 versus BMSCs.
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PFIGURE 3. Collagen content and structure in the remote myocardium. A–D, Representative confocal micrographs (left ventricular sections) showing the
fibrillar collagen network (stained with picrosirius red, arrows) in normal myocardium (No MI,A), and in the remote (noninfarcted) myocardium of infarcted
animals, 28 days after implantation of medium (B), bone marrow stromal cells (BMSC, C) or timp-3-transfected BMSCs (BMSC-T3, D). Cardiomyocytes
appear green due to autofluorescence. Scale bar ¼ 50 mm in (A–D). Collagen fibers and connectivity were clearly preserved in the BMSC group and further
preserved in the BMSC-T3 group. E–G, Collagen content (expressed as% of pixel2, E), fibril length (F), and fibril diameter (G), determined for all 4 groups
(n ¼ 6 per group for Medium, BMSC, BMSC-T3; n ¼ 4 for No MI) by computer image analysis of confocal stacks, were all increased to No MI levels by
BMSC-T3 implantation. Data are mean  standard error of the mean. *P<0.05 versus medium, #P< .05 versus BMSC, yP< .05 versus No MI.zone (Figure 4, A toG). BMSC implantation significantly in-
creased capillary densities in this region early (by day 3, P<
.05 vs BMSC-T3 and medium). Interestingly, TIMP-3 over-
expression temporarily reduced the effect of the implanted
cells on capillary formation early after implantation (at day
3) but not later, as capillary densities were similarly elevated
(P< .05) relative to medium controls in both BMSC and
BMSC-T3 groups at day 7 after implantation (Figure 4, H).
TIMP-3 overexpression enhanced the preservation of
systolic function by BMSCs. Echocardiographic measure-
ments of LV end diastolic dimension showed significant LV
dilatation in the medium-implanted group as early as 3 days
after MI, worsening until the end of the experiments at 28
days (Figure 5, A to C). BMSC and BMSC-T3 implantation
significantly reduced LV dilatation (relative to controls) at 7
and 28 days followingMI (P<.05 group and time effects by
2-way ANOVA), with beneficial effects evident earlier (by
day 3) in the BMSC-T3 group (Figure 5, C).
Systolic function decreased progressively after MI in the
medium control group. BMSC implantation significantly
improved systolic function (FAC) compared with the me-
dium control group at days 7 (P<.05) and 28 (P<.05) fol-
lowing treatment. TIMP-3 overexpression further increased
the functional benefits of cell implantation (P< .05 for
BMSC-T3 vs BMSC at days 3 and 28), and the effects
were evident earlier, by 3 days following cell treatment
(Figure 5, D).
Cell transplantation preserved LV morphometry.
Twenty-eight days after cell implantation, morphologic
analysis demonstrated a significantly smaller (P< 0.01)
scar area in the cell-implanted groups than in the medium
control group (Figure 5, E). In agreement with the echocar-
diographic data, cell transplantation also reduced LV dilata-
tion to a level similar to that seen in noninfarcted
myocardium (Figure 5, F).
DISCUSSION
Cell transplantation improves ventricular function after
an MI,4,20-23 primarily due to paracrine cytokine activation
that induces angiogenesis, marrow progenitor cell recruit-
ment, and matrix modulation1; however, functional recov-
ery may be enhanced by cell-based gene therapy. Here,
BMSCs transplanted immediately after MI preserved ma-
trix structure in the remote (viable) myocardium of timp-
3/ mice, and overexpressing TIMP-3 in the implanted
BMSCs significantly enhanced these effects. The timp-3/
mice exhibit exaggerated ECM degradation and ventricu-
lar dilatation following coronary ligation,13-15 which may
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heart failure after an MI (perhaps due to an inadequate
TIMP injury response).6,18 This preliminary study estab-
lishes the proof of concept that cell-based gene therapy
could modify matrix modulation following an MI. Studies
in wild-type rodents and large animals will be required to
determine whether the approach is clinically applicable. If
it is, then this technique might provide an opportunity to
FIGURE 4. Capillary density. A–G, Representative light micrographs (3250) showing CD31 staining (vascular structure; brown in color) in the infarct
border zone (A–F) of hearts at days (D) 3 and 7 after implantation of medium (A, D), bone marrow stromal cells (BMSC, B, E) or timp-3-transfected
BMSCs (BMSC-T3, C, F). Normal myocardium (No MI, G) was a positive control. Scale bar ¼ 25 mm in A–G. H, Blood vessel density (expressed as
number of capillaries per mm2; n ¼ 5 per group per time point) was significantly greater at D3 with BMSC implantation compared with BMSC-T3.
By D7, vessel density was equally increased in both cell transplant groups. Data are mean  standard error of the mean. *P< .05 versus medium,
#P< .05 versus BMSC.
The Journal of Thoracic and Cardiovascular Surgery c Volume 137, Number 2 477
Cardiopulmonary Support and Physiology Angoulvant et al
C
S
P478 The Journal of Thoracic and Cardiovascular Surgery c February 2009
Angoulvant et al Cardiopulmonary Support and Physiology
C
S
Prejuvenate stem cells in elderly patients whose natural re-
generative capacity is diminished.
Cell-based gene therapy may boost the paracrine effects
of cell transplantation. Ventricular function was enhanced
by transfecting implanted cells with the genes for stem cell
factor, vascular endothelial growth factor (VEGF), insulin-
like growth factor, and/or Akt.20-24 This is the first study
to show that TIMP-3 overexpression in the implanted cells
enhanced the preservation of the matrix structure after an
MI. The early reduction in capillary density by BMSC-T3s
may have coincided with the early inhibition of MMPs, as
matrix degradation is required for endothelial cell mobiliza-
tion and the branching of new blood vessels. The early
effects on capillary density could also be attributed to
alternate (but slower) angiogenic pathways. Alternatively,
TIMP-3 overexpression may have inhibited VEGF-medi-
ated angiogenesis and induced other secondary effects.25
We have previously suggested that cell transplantation af-
ter an MI may modify matrix remodeling in the remote myo-
cardium as well as in the infarct area, but this effect has been
difficult to demonstrate due to the multiple events associated
with coronary ligation.6,13 In a hamster model of progressive
cardiomyopathy, we showed that cell implantation pre-
served the collagen network and the regional MMP/TIMP
balance in both the implanted area and the remote myocar-
dium.4 In rats following an MI, we found that cells im-
planted into the infarct area reduced matrix remodeling in
that area.26 The current study demonstrated that BMSCs im-
planted into the infarct area of timp-3/mice promoted ma-
trix preservation not only in that area but also in the remote
myocardium. This finding provides further support for the
theory that matrix homeostasis in the remote myocardium
is a critical determinant for the improvement of cardiac func-
tion by implanted cells.
In addition to affecting matrix modulation, TIMP-3 over-
expression may also have contributed to the reduced cardiac
production of TNF-a, which induces adverse cardiac remod-
eling and ventricular dysfunction.27 TIMP-3 is a potent,
endogenous inhibitor of ADAMs (a disintegrin and a metal-
loproteinase domain) and TNF-a converting enzyme,28,29
which are increased in the hearts of timp-3/ mice.13 In
the current study, implanting cells overexpressing TIMP-3significantly modified the early pattern of post-MI TNF-
a levels relative to that observed with vector-transfected
BMSCs. TNF-a also increases apoptosis andMMP gene ex-
pression,27 which may explain further reductions in cell loss
and matrix structural remodeling in mice implanted with the
gene-enhanced cells.
Cell-based gene therapy may permit the regulated, tran-
sient MMP inhibition that has not been achieved by current
approaches.10 Jayasankar and colleagues12 overexpressed
TIMP-1 by intramyocardial gene transfer in the border
zone after coronary ligation in rats. They observed transient
inhibition of MMP-1 activity as well as limited improve-
ments in systolic function and geometric remodeling.
Gene-enhanced cells influence not only the infarct (im-
planted) area but also the border zone and the noninfarcted
myocardium.21,23 We previously reported that the transient
release of angiogenic gene products following cell-based
gene therapy produced prolonged (6-month) improvements
in capillary density and cardiac function.2 In the current
study, we observed a transient (6-day) elevation of
TIMP-3 mRNA in the transfected cells. We believe that
short-term, regulated amplification of the TIMP response
with this clinically relevant approach may confer long-
term benefits for matrix modulation in patients. However,
we did not determine the number of cells engrafting in the
heart, and we did not compare our results to those with
gene therapy alone or gene therapy using inert cells.
Paracrine mediators likely act through multiple, diverse,
and interrelated mechanisms to produce synergistic effects
on the remodeling process. However, although future stud-
ies will be required to determine whether TIMP-3-enhanced
cell transplantation will modify post-MI matrix remodeling
in wild-type mice or humans, the current study suggests
that cell-based gene therapy is a potentially effective method
to generate transient MMP inhibition and achieve functional
recovery following an MI.
R.-K.L. is a Career Investigator of the Heart and Stroke Founda-
tion of Canada and holds a Canada Research Chair in cardiac regen-
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timp-3/ mice and Heather McDonald Kinkaid for manuscript
preparation and editing.FIGURE 5. Left ventricular (LV)morphometry and function. A, Representative macrographs of heart slices at 28 days after myocardial infarction (MI) and
implantation of medium, bonemarrow stromal cells (BMSC), or timp-3-transfected-BMSCs (BMSC-T3). Increased infarct size and LV dilatation is apparent in
medium control hearts compared with those from BMSC and BMSC-T3 groups. B, These observations are confirmed by echocardiographic parasternal small-
axis M mode images of the hearts for morphologic study. C, By echocardiography (n¼ 6 per group per time point), LV dilatation (body weight-indexed LV
end diastolic dimension in mm/g) over 28 days following MI was significantly reduced (relative to medium controls) after implantation of BMSC (at days 7
and 28; P<.05) and BMSC-T3 (at days 3, 7, 28; P<.01). D, LV systolic function (fractional area change in%) over 28 days followingMI was significantly
preserved after implantation of BMSC (compared with medium controls) and BMSC-T3 (compared with BMSC andmedium groups). E, F, By morphometric
assessment (n¼ 6 per group), LV infarcted areas (expressed as% of LV surface, E), and body weight–indexed LV chamber volumes (normal heart [No MI,
n ¼ 3] as control, F) were significantly smaller (compared with medium controls) at 28 days (D) after BMSC or BMSC-T3 implantation. No significant dif-
ferences were observed between BMSC and BMSC-T3 groups. Data are mean  standard error of the mean. *P< .05 versus medium.
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PAPPENDIX E1
Supplementary Methods
The bone marrow stromal cells (BMSCs) employed in these
studies have been previously employed to improve ventric-
ular function after a myocardial infarction and to act as a car-
rier for cell-based gene therapy. These cells are particularly
appropriate for this purpose because of their ability not only
to induce angiogenesis but also to transdifferentiate into a va-
riety of cell types required for infarct healing: endothelial,
smooth muscle cells, and myofibroblasts. However, BMSCs
are not easily identified by surface markers and therefore are
not easily separated by common cell-sorting techniques. In-
stead, BMSCs are identified by their ability to adhere to plas-
tic surfaces and to rapidly expand in response to cytokines.
In Vitro Studies
BMSCs: Isolation, expansion, and characterization.
BMSCs were isolated from C57BL/6 mice and cultured as
previously described.E1 Whole bone marrow was plated in
Iscove’s modified Dulbecco’s medium (Gibco, Rockville,
Md) supplemented with 10% fetal bovine serum (Gibco),
penicillin (100 U/mL), and streptomycin (100 U/mL). Cells
were cultured at 37C with 5% CO2 in humid atmosphere.
Nonadherent cells were removed by aspiration 48 hours
later. Adherent cells were harvested in 0.05% Trypsin
solution with 1 mmol ethylenediaminetetraacetic acid and
subcultured. Cultured cell phenotype was assessed by fluo-
rescence-activated cell sorting (FACS), using fluorescein
isothiocyanate–conjugated or phycoerythrin-conjugated
monoclonal antibodies recognizing Sca-1, CD81, CD34,
CD45, CD31, and c-kit (Becton Dickinson, Franklin Lakes,
NJ). Analysis was with an EPICS XL-MCL flow cytometer
(Coulter, Beckman, Fullerton, Calif) equipped with Expo32
ACD Xa software.
Generation of BMSCs overexpressing murine tissue in-
hibitor of matrix metalloproteinase-3. cDNA for murine
tissue inhibitor of matrix metalloproteinase-3 (TIMP-3) was
cloned into pcDNA3.1þ(Invitrogen, Carlsbad, Calif) as pre-
viously described.E2 The purified plasmid was transfected
into BMSCs (BMSC-T3) by liposomal transfection using
lipofectamine 2000 (Invitrogen) as per manufacturer’s in-
structions. Cotransfection with pSV-b-galactosidase control
vector (Promega, Madison, Wis) was performed to assess
transfection efficiency. b-galactosidase expression was as-
sessed after staining of BMSCs as per manufacturer’s in-
structions (Promega). Blue-stained b-galactosidase positive
cells were counted on 10 random fields and expressed as per-
cent of total cells per field. BMSCs transfected with unmod-
ified pcDNA3.1þwere stained as negative controls.
Cellular TIMP-3 expression. Cellular TIMP-3 mRNA
levels at 0, 1, 2, 3, and 6 days after transfection (n ¼ 5 per
The Journal of Thoracic and Cargroup per time point) were assessed by semiquantitative re-
verse-transcriptase polymerase chain reaction, using specific
primers, as previously described.E3
Protein levels of synthesized (BMSC lysate) and secreted
(supernatant) TIMP-3 were evaluated with an immunoblot-
ting procedure using a polyclonal rabbit anti-human anti-
body for TIMP-3 (1:500, Triple Point Biologics, Forest
Groves, Orel) at 0, 3, 6, and 10 days after gene transfection
(n ¼ 6 per group per time point).
Cellular matrix metalloproteinase-2 expression and
activity. Protein levels of matrix metalloproteinase-2
(MMP-2) in the cultured cells and culture medium 3 days
(n ¼ 6 per group) after timp-3 transfection were quantified
by Western blot, using a rabbit anti-human antibody against
MMP-2 (1:1000, Chemicon International, Billerica, Mass.),
as previously described.E4
Activities of MMP-2 were evaluated at 3 days after gene
transfection using gelatin zymography, as previously descri-
bed.E4 Equal amounts (10 mg) of protein (n ¼ 6 per group)
were fractionated by 10% zymography gels impregnated
with 0.1% gelatin (Novex, Invitrogen). Gels were renatured
with 23 2.5% Triton X-100 washes for 30 minutes at room
temperature. The gels were then equilibrated with develop-
ing buffer (49.1 mmol/L Tris, 4.81 mmol/L CaCl2,
0.002% NaN3) at room temperature for 15 minutes with ag-
itation. Finally, gels were incubated with developing buffer
18 to 20 hours at 37C. Coomassie blue R-250 (Sigma
Chemical Co, St Louis, Mo) staining was used to detect en-
zymatic activity; following staining, areas of gelatinolytic
activity appeared as clear bands against the dark blue back-
ground. Bands obtained from immunoblot and gelatin
zymography were quantified using densitometric analysis.
The latent (pro) and active forms of MMP-2 (72 and 68
kDa, respectively) were detected. Molecular weights of the
bands were estimated using recombinant MMP-2 protein.
Integrated density values (band area X relative intensity)
of active MMP-2 were used as markers of MMP-2 activa-
tion.
In Vivo Studies
Functional assessment. Left ventricular (LV) dilatation
and systolic function were evaluated by echocardiography
(Sequoia C256 System, Siemens Medical; 15-MHz linear
array transducer) prior to and 3, 7, and 28 days after MI
and cell or medium implantation (n ¼ 6 per group).
M-mode and 2-dimensional images were obtained in the
parasternal short axis at the level of the papillary muscles.
For each measurement, 3 consecutive cardiac cycles were
recorded and averaged by a single blinded examiner. LV
end diastolic dimension was determined inM-mode imaging
and indexed to the animal’s body weight recorded at the time
of echocardiography. In 2-dimensional imaging, the LV end
diastolic area (LVEdA) was determined as the largest cavity
diovascular Surgery c Volume 137, Number 2 480.e1
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Psize and the LV end systolic area (LVEsA) as the smallest.
Fractional area change (FAC) was calculated as follows:
FAC ¼ ((LVEdA  LVEsA)/LVEdA) 3100. Afterward,
hearts from each group were fixed for morphometric and col-
lagen analyses.
Morphometric assessment. At 28 days after implantation
(n¼ 6 each for medium, BMSC, BMSCs transfected 3 days
earlier with TIMP-3 plasmid [BMSC-T3] groups; n ¼ 3 for
normal myocardium), following perfusion fixation with
buffered 10% formalin at controlled ventricular pressure,
left ventricles were cut into 1-mm-thick transverse slices
from apex to base. Heart slices were photographed with
a digital camera, and unmagnified images were analyzed
by a blinded observer using Image J software. The border
between infarcted and noninfarcted myocardium was clearly
identifiable in each image (the infarcted myocardium ap-
peared visibly thinner and paler in color than the nonin-
farcted myocardium). Infarct size was measured as
described by Takagawa and colleagues,E5 with modifica-
tions. Briefly, epicardial infarct length and epicardial cir-
cumference of LV myocardium were manually traced and
automatically measured in serial digital images. To calculate
infarct and LV areas for each slice, infarct length or LV cir-
cumference were multiplied by the 1-mm thickness. To cal-
culate infarct size (expressed as a percentage), the sum of
infarct areas from all slices was divided by the sum of LV
areas from all slices (including those without infarct scar)
and multiplied by 100. LV chamber volume was measured
in the same manner and indexed by body weight (mL/kg).
SUPPLEMENTARY RESULTS
In Vitro Studies
Characterization of cultured BMSCs. The phenotypes of
cultured BMSCs at passages 10, 20, and 40 were evaluated
by FACS analysis. The cell population was homogenous,
and more than 99% of cells stably expressed Sca-1þ,
CD81þ, CD34, CD45, CD31, c-kit, without contamina-
tion by hematopoietic stem cells or endothelial progenitor
cells. BMSCs from passage 20 were used in this study to im-
prove cardiac function and as carriers of the timp-3 gene.
Cellular TIMP-3 expression. Gene transfection effi-
ciency, evaluated by staining for b-galactosidase expression
(Figure 1, A), was 15%  2% at 3 days after transfection.
TIMP-3 mRNA levels in the gene-transfected cells were sig-
nificantly greater (P< .01) than those in the vector-trans-
fected cells for the 6-day duration of the study (Figure 1, B
and C). TIMP-3 protein levels in the BMSC lysate (synthe-
sized TIMP-3) and supernatant (secreted TIMP-3) were
greatly elevated from baseline for at least 6 days after
timp-3 transfection (P< .01 for all groups, Figure 1, D
and E).
CellularMMP-2 expression and activity. Gelatin zymog-
raphy showed a significant reduction in MMP-2 activity in
the medium cultured with BMSC-T3 compared with that
cultured with BMSC at 3 days after transfection (P< .01;
Figure 1, F), though immunoblot analysis showed no differ-
ence in MMP-2 expression between the 2 groups (Figure 1,
G). These data confirm that BMSC-T3 cells expressed func-
tional TIMP-3 following gene transfection.
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